Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tyrocutin
- Development stage
- Unknown
- Lead developer
- Andrew Martin
- Administration
- Oral
01
Overview
Tyrocutin is an oral, plant-derived bioactive complex developed by Scientis. It is composed of cuscutin, p-coumaric acid, ferulic acid, and oligomeric proanthocyanidins (OPCs). Tyrocutin acts as an oral tyrosinase inhibitor designed to manage skin pigmentation, particularly melasma, from the inside out. By targeting tyrosinase activity, inflammatory signaling, UV-induced oxidative stress, and dermal microcirculation, it helps regulate melanin production, protect against photoaging, and promote skin tone evenness and luminosity. It is marketed as a key component of the Cyspera Total Skin supplement and has been evaluated both as a monotherapy and as an adjunct to picosecond laser therapy.
- Brand names
- Cyspera Total Skin
- Other names
- TyroCutinTyrocutin complex
02
Targets
TYR (Tyrosinase)
Beyond the preview
Go deeper on Tyrocutin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tyrocutin.